166 related articles for article (PubMed ID: 25469883)
21. Genomic classifications of renal cell carcinoma: a critical step towards the future application of personalized kidney cancer care with pan-omics precision.
Hsieh JJ; Le V; Cao D; Cheng EH; Creighton CJ
J Pathol; 2018 Apr; 244(5):525-537. PubMed ID: 29266437
[TBL] [Abstract][Full Text] [Related]
22. Understanding the microbiome: Emerging biomarkers for exploiting the microbiota for personalized medicine against cancer.
Rajpoot M; Sharma AK; Sharma A; Gupta GK
Semin Cancer Biol; 2018 Oct; 52(Pt 1):1-8. PubMed ID: 29425888
[TBL] [Abstract][Full Text] [Related]
23. Selected news from the 2014 Genitourinary Cancers Symposium: translating novel strategies into clinical practice.
Bianconi M; Santoni M; Massari F; Faloppi L; Del Prete M; Giampieri R; Ciccarese C; Modena A; Tortora G; Scartozzi M; Cascinu S
Future Oncol; 2014 Nov; 10(14):2103-6. PubMed ID: 25471023
[TBL] [Abstract][Full Text] [Related]
24. Prostate cancer molecular profiling: the Achilles heel for the implementation of precision medicine.
Oliveira-Barros EG; Nicolau-Neto P; Da Costa NM; Pinto LFR; Palumbo A; Nasciutti LE
Cell Biol Int; 2017 Nov; 41(11):1239-1245. PubMed ID: 28477422
[TBL] [Abstract][Full Text] [Related]
25. [The role of biomarkers in the diagnosis, prognosis and therapy of patients with immuno-oncological treatments of genito-urinary carcinomas].
Compérat E; Eymerit C; Moroch J; Varinot J
Aktuelle Urol; 2018 Apr; 49(2):171-177. PubMed ID: 29587322
[TBL] [Abstract][Full Text] [Related]
26. Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent.
Chatalic KL; Heskamp S; Konijnenberg M; Molkenboer-Kuenen JD; Franssen GM; Clahsen-van Groningen MC; Schottelius M; Wester HJ; van Weerden WM; Boerman OC; de Jong M
Theranostics; 2016; 6(6):849-61. PubMed ID: 27162555
[TBL] [Abstract][Full Text] [Related]
27. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer.
Ghosh A; Heston WD
J Cell Biochem; 2004 Feb; 91(3):528-39. PubMed ID: 14755683
[TBL] [Abstract][Full Text] [Related]
28. Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine.
Kamel HFM; Al-Amodi HSAB
Genomics Proteomics Bioinformatics; 2017 Aug; 15(4):220-235. PubMed ID: 28813639
[TBL] [Abstract][Full Text] [Related]
29. Next-Generation Sequencing and Applications to the Diagnosis and Treatment of Lung Cancer.
Kruglyak KM; Lin E; Ong FS
Adv Exp Med Biol; 2016; 890():123-36. PubMed ID: 26703802
[TBL] [Abstract][Full Text] [Related]
30. Cancer Precision Medicine: Why More Is More and DNA Is Not Enough.
Schütte M; Ogilvie LA; Rieke DT; Lange BMH; Yaspo ML; Lehrach H
Public Health Genomics; 2017; 20(2):70-80. PubMed ID: 28595192
[TBL] [Abstract][Full Text] [Related]
31. Pathology and molecular updates in tumors of the prostate: towards a personalized approach.
Gasparrini S; Cimadamore A; Mazzucchelli R; Scarpelli M; Massari F; Raspollini MR; Galosi AB; Lopez-Beltran A; Cheng L; Montironi R
Expert Rev Mol Diagn; 2017 Aug; 17(8):781-789. PubMed ID: 28598696
[TBL] [Abstract][Full Text] [Related]
32. The evolving potential of companion diagnostics.
Khoury JD
Scand J Clin Lab Invest Suppl; 2016; 245():S22-5. PubMed ID: 27433788
[TBL] [Abstract][Full Text] [Related]
33. Colorectal cancer molecular profiling: from IHC to NGS in search of optimal algorithm.
Furtado LV; Samowitz WS
Virchows Arch; 2017 Aug; 471(2):235-242. PubMed ID: 28551725
[TBL] [Abstract][Full Text] [Related]
34. Current and future molecular profiling of cancer by next-generation sequencing.
Shibata T
Jpn J Clin Oncol; 2015 Oct; 45(10):895-9. PubMed ID: 26292697
[TBL] [Abstract][Full Text] [Related]
35. Outlier analysis of functional genomic profiles enriches for oncology targets and enables precision medicine.
Zhu Z; Ihle NT; Rejto PA; Zarrinkar PP
BMC Genomics; 2016 Jun; 17():455. PubMed ID: 27296290
[TBL] [Abstract][Full Text] [Related]
36. Next revolution in molecular theranostics: personalized medicine for urologic cancers.
Aoun F; Kourie HR; Artigas C; Roumeguère T
Future Oncol; 2015; 11(15):2205-19. PubMed ID: 26235183
[TBL] [Abstract][Full Text] [Related]
37. Molecular biomarkers to guide precision medicine in localized prostate cancer.
Smits M; Mehra N; Sedelaar M; Gerritsen W; Schalken JA
Expert Rev Mol Diagn; 2017 Aug; 17(8):791-804. PubMed ID: 28635333
[TBL] [Abstract][Full Text] [Related]
38. Genomic medicine and risk prediction across the disease spectrum.
Kotze MJ; Lückhoff HK; Peeters AV; Baatjes K; Schoeman M; van der Merwe L; Grant KA; Fisher LR; van der Merwe N; Pretorius J; van Velden DP; Myburgh EJ; Pienaar FM; van Rensburg SJ; Yako YY; September AV; Moremi KE; Cronje FJ; Tiffin N; Bouwens CS; Bezuidenhout J; Apffelstaedt JP; Hough FS; Erasmus RT; Schneider JW
Crit Rev Clin Lab Sci; 2015; 52(3):120-37. PubMed ID: 25597499
[TBL] [Abstract][Full Text] [Related]
39. Clinical tumor sequencing: opportunities and challenges for precision cancer medicine.
Damodaran S; Berger MF; Roychowdhury S
Am Soc Clin Oncol Educ Book; 2015; ():e175-82. PubMed ID: 25993170
[TBL] [Abstract][Full Text] [Related]
40. Systemic Therapy for Metastatic Colorectal Cancer: From Current Standards to Future Molecular Targeted Approaches.
Atreya CE; Yaeger R; Chu E
Am Soc Clin Oncol Educ Book; 2017; 37():246-256. PubMed ID: 28561718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
